SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-018828
Filing Date
2022-12-20
Accepted
2022-12-20 16:05:39
Documents
13
Period of Report
2022-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20221219x8k.htm   iXBRL 8-K 37230
2 EX-10.1 adap-20221219xex10d1.htm EX-10.1 59549
  Complete submission text file 0001558370-22-018828.txt   227533

Data Files

Seq Description Document Type Size
3 EX-101.SCH adap-20221219.xsd EX-101.SCH 3373
4 EX-101.LAB adap-20221219_lab.xml EX-101.LAB 15976
5 EX-101.PRE adap-20221219_pre.xml EX-101.PRE 10795
7 EXTRACTED XBRL INSTANCE DOCUMENT adap-20221219x8k_htm.xml XML 4964
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 221474765
SIC: 2836 Biological Products, (No Diagnostic Substances)